The Court of Appeals for the Federal Circuit has affirmed previous rulings in favor of Liquidia Corporation in patent litigation case filed by United Therapeutics Corporation. The district court previously ruled that Liquidia's product YUTREPIA doesn't infringe on two specific patents and the Patent Trial and Appeal Board reaffirmed that all claims in the second patent are unpatentable.